Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Blood (2024) 144 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2024-199287

Published: 2024

Journal Articles

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Blood (2024) 144 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2024-200239

Published: 2024

Journal Articles

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

Charles Craddock, David Marks, Victoria Potter, Wendy A Ingram, Rebecca Collings, Eleni Tholouli, Rachel Protheroe, Hugh Allen, Alex Ross, Dawn Farrar, Shamyla Siddique, Rebecca Bishop, Ronjon Chakraverty

Blood (2023) 142 (Supplement 1): 5097.

https://doi.org/10.1182/blood-2023-188490

Published: 2023

Journal Articles

Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Ryan M. Carr, MD PhD, Terra Lasho, PhD, Christy Finke, BS, Abhishek A. Mangaonkar, MBBS, Christopher Pin, PhD, Kurt Berger, Tamas Ordog, MD, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Alexandre Gaspar Maia, PhD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134964

Published: 2020

Journal Articles

ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility

Moritz Binder, MDMPH, Sandeep Potluri, MA, MBBChir, MRCP, Ryan M. Carr, MD PhD, Terra Lasho, PhD, Christy Finke, BS, Abhishek A. Mangaonkar, MBBS, Christopher Pin, PhD, Kurt Berger, Tamas Ordog, MD, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Alexandre Gaspar Maia, PhD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134977

Published: 2020

Journal Articles

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Blood (2019) 134 (Supplement_1): 1710.

https://doi.org/10.1182/blood-2019-123877

Published: 2019

Journal Articles

Epigenomic Determinants of Transcriptional Activity in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Alexandre Gaspar Maia, PhD, Ryan M. Carr, MD PhD, Christopher Pin, PhD, Kurt Berger, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 2987.

https://doi.org/10.1182/blood-2019-123191

Published: 2019

Journal Articles

Distal Enhancer Elements in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Alexandre Gaspar Maia, PhD, Ryan M. Carr, MD PhD, Terra Lasho, PhD, Thomas E. Witzig, MD, Christopher Pin, PhD, Kurt Berger, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 2981.

https://doi.org/10.1182/blood-2019-124917

Published: 2019

Journal Articles

Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Ryan Carr, MD PhD, Nathalie Droin, PhD, Abhishek A Mangaonkar, MBBS, Giacomo Coltro, MD, Luciana L Almada, PhD, David Marks, PhD, Kurt Berger, Terra Lasho, PhD, Naseema Gangat, MBBS, Christopher Pin, PhD, Martin Fernandez-Zapico, MD, Eric Solary, MD PhD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 4232.

https://doi.org/10.1182/blood-2019-122187

Published: 2019

Journal Articles

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Partow Kebriaei, MD, Daniel J. DeAngelo, MD, Anjali S. Advani, MD, Susan M. O'Brien, MD, David Marks, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Tao Wang, Erik Vandendries, MD PhD, A. Douglas Laird, PhD, Sonja Nick, MSc, Matthias Stelljes, MD

Blood (2018) 132 (Supplement 1): 4031.

https://doi.org/10.1182/blood-2018-99-110552

Published: 2018

Journal Articles

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Vasudha Rao, MD, Katherine Clesham, Jack Luke Bartram, MD, Phil Ancliff, Sara Ghorashian, FRCPath, PhD, David O'Connor, Vesna Pavasovic, Anupama Rao, MD, Sujith Samarasinghe, Carole Cairns, David Marks, David Taussig, PhD MRCP, FRCPath, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 5201.

https://doi.org/10.1182/blood-2018-99-117051

Published: 2018

Journal Articles

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

David Marks, Wendy Gidman, PhD MSc, BPharm, Heather M Wieffer, PhD, Lirong Zhang, MSc, Ze Cong, PhD MS, Shweta Shah

Blood (2018) 132 (Supplement 1): 5865.

https://doi.org/10.1182/blood-2018-99-118029

Published: 2018

Journal Articles

Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse

Dina Ahmed Said Aly Okasha, MBBS, MSc, Amy A Kirkwood, Krisztina Zuborne Alapi, MSc, Rachel J Mitchell, MSc, Pedro Santos e Sousa, MD PhD, Daniel Leongamornlert, PhD, Elli Papaemmanuil, PhD, David Marks, MD PhD, Ronjon Chakraverty, BMBS, PhD, Adele K Fielding, MBBS,PhDFRCP,FRCPath

Blood (2017) 130 (Supplement 1): 1317.

https://doi.org/10.1182/blood.V130.Suppl_1.1317.1317

Published: 2017

Journal Articles

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Partow Kebriaei, MD, Matthias Stelljes, MD, Daniel J. DeAngelo, MD, Nicola Goekbuget, MD, Hagop M. Kantarjian, MD, Anjali S. Advani, MD, Akil Merchant, MD, Wendy Stock, MD, Tao Wang, PhD, Hui Zhang, Fausto Loberiza, Erik Vandendries, MD PhD, David Marks

Blood (2017) 130 (Supplement 1): 886.

https://doi.org/10.1182/blood.V130.Suppl_1.886.886

Published: 2017

Journal Articles

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Blood (2016) 127 (20): 2427–2438.

https://doi.org/10.1182/blood-2015-11-679639

Published: 2016

Includes: Supplemental data

Journal Articles

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Chezi Ganzel, Wang Xin Victoria, Adele K. Fielding, MB, BS, PhD, Jacob M. Rowe, MD, Susan M Richards, PhD, Georgina Buck, Rajesh Chopra, PhD, I. Jill Durrant, David Marks, MD PhD, Ian M. Franklin, MD, Andrew K McMilan, Mark R Litzow, MD, Elisabeth Paietta, PhD, Selina Luger, MD, Peter H Wiernik, Dan Douer, MD, Hillard M. Lazarus, MD, Martin S Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2015) 126 (23): 795.

https://doi.org/10.1182/blood.V126.23.795.795

Published: 2015

Journal Articles

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Dina Okasha, Amy A Kirkwood, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Emma Lawrie, Andrew McMillan, PhD, Tobias F. Menne, MD PhD FRCPath, Nick Morley, Clare Rowntree, Deborah Susan Richardson, MDFRCPath,FRCP,MA,MBBChir, Paul Smith, Adele K. Fielding, MB BS, PhD, David Marks, MD PhD

Blood (2015) 126 (23): 733.

https://doi.org/10.1182/blood.V126.23.733.733

Published: 2015

Journal Articles

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Bella Patel, MB, BS, MD, A Kirkwood, Aditi Dey, Clare Rowntree, Andrew McMillan, FRCP, FRCPath, PhD, David Marks, MD, PhD, Tobias Menne, Paul Smith, PhD, Simon Purnell, Lynda Micklewright, Adele K Fielding, MB, BS, PhD

Blood (2013) 122 (21): 3900.

https://doi.org/10.1182/blood.V122.21.3900.3900

Published: 2013

Journal Articles

An Intensive Model Of Care For Adults With Sickle Cell Disease That Rapidly Reduces Hospital Admissions, Readmissions and Cost

Kathryn L. Koch, MSN, FNP-BC, Cynthia L. Leonard, MSN, RN, Katherine Bagemihl, MS, David Marks, MD, MBA, Thomas C. Abshire, Joshua J. Field, MD, MS

Blood (2013) 122 (21): 773.

https://doi.org/10.1182/blood.V122.21.773.773

Published: 2013

Journal Articles

Alemtuzumab Used with Fludarabine and Cyclophosphamide (FCC) for Stem Cell Transplantation in Acquired Aplastic Anemia Is Associated with a Low Risk of Graft Versus Host Disease and Viral Infections and with Sustained Engraftment.

Judith C W Marsh, Vikas Gupta, ZiYi Lim, MD, David Marks, Edward C. Gordon-Smith, MD, BM, BCh, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 1084.

https://doi.org/10.1182/blood.V114.22.1084.1084

Published: 2009

NARROW

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia

ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Epigenomic Determinants of Transcriptional Activity in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Distal Enhancer Elements in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

An Intensive Model Of Care For Adults With Sickle Cell Disease That Rapidly Reduces Hospital Admissions, Readmissions and Cost

Alemtuzumab Used with Fludarabine and Cyclophosphamide (FCC) for Stem Cell Transplantation in Acquired Aplastic Anemia Is Associated with a Low Risk of Graft Versus Host Disease and Viral Infections and with Sustained Engraftment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only